Cancer Research 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches external reviewers, an editor evaluates whether the cancer-research mechanism and broad cancer significance meet the journal's expectations. AACR reports a 3.8-day median for decisions without peer review (all AACR journals, 2024) but publishes no desk-rejection percentage for Cancer Research.

A desk rejection can mean the editor concluded that the work would fit better at a sister AACR journal (Cancer Discovery for top-tier cancer discovery, Clinical Cancer Research for clinical-translation, Molecular Cancer Therapeutics for therapeutics, Cancer Prevention Research for prevention, Cancer Immunology Research for immunology, Cancer Epidemiology, Biomarkers & Prevention for epidemiology) or that the cancer-research mechanism bar is not met.

AACR screens each submission for manuscript completeness and editorial integrity. For initial submission, AACR asks that the text be clean with all manuscript sections and items present and legible, the author list complete and accurate, and a conflict-of-interest statement present, and it strongly encourages a cover letter and a single manuscript file containing the main text and all display items. AACR's policies also cover animal approval statements, data availability statements, and study-specific reporting guidelines, for example ARRIVE for animal work and CONSORT for randomized trials.

An editor reads the paper and evaluates cancer-research mechanism and broad cancer significance. AACR's median for a first decision without peer review was 3.8 days across its journals in 2024.

AACR's transfer page says that, although it is not typical, editors may reach out in confidence to the editors of another AACR journal to gauge their interest in considering the manuscript. If the other journal's editors invite the transfer, the decision letter includes language encouraging transfer to that journal, and you are under no obligation to submit there.

The handling editor assigns appropriate expert external reviewers based on the scientific content of the manuscript. Authors can suggest reviewers, who may be editorial board members or outside experts, and suggested reviewers are considered and used at the editor's discretion. AACR publishes no reviewer-recruitment timing.

AACR reports a median of 35 days (average 37 days) from submission to a first decision with peer review across its journals in 2024. 98 percent of first decisions with peer review had comments from 2 or more reviewers. AACR describes its peer review as single-blind, with reviewers asked to give an objective overall recommendation supported by detailed comments on the quality and originality of the science.

After reports return, the handling editor assesses the reviewers' comments and recommendations and either renders a decision or recommends one to the Editor(s)-in-Chief. Only 3.1 percent of first decisions with peer review across AACR journals exceeded 60 days in 2024. AACR publishes no total submission-to-acceptance time.

• Rejection within the first few days: An editorial decision on scope or fit.

• Rejection within about a week: Still within AACR's typical desk-decision window (median 3.8 days, average 4.4 days).

• Still Under Review after 2 weeks: A good sign, since AACR's desk decisions average 4.4 days; the paper has most likely passed the editorial screen.

• Still Under Review after 60 days (about 9 weeks): You are in the slowest 3 percent (per AACR's 3.1 percent of first decisions with peer review exceeding 60 days). A polite inquiry through SmartSubmit is appropriate.

• Status changes without a decision email: SmartSubmit's Check Status page gives a detailed status report; AACR does not define individual status labels publicly.

This is the most common anxiety we hear from Cancer Research authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you right at Cancer Research's 35-day first-decision median. Reports may already be in editorial synthesis with the handling editor.

Reviewer recruitment and reviewer turnaround both affect timing, and AACR publishes no breakdown of the two. If the portal still says Under Review past 60 days, you would be in the slowest 3 percent of AACR first decisions with peer review; a polite inquiry is appropriate.

Avoid emailing the editorial office during the first 5 weeks; an inquiry before the 35-day median is unlikely to accelerate the timeline.

If your Cancer Research paper is rejected after review, the natural cascade depends on what the reviewers and Senior Editor cited:

Cancer Discovery is the natural AACR top-tier cancer discovery cascade. AACR supports manuscript-transfer with reviewer reports preserved via the AACR manuscript transfer pathway.

Clinical Cancer Research is the AACR cascade for clinical-translation papers. Clinical Cancer Research also uses AACR's SmartSubmit system; its editorial contact on AACR's journal selection page is ccr@aacr.org.

Molecular Cancer Therapeutics is the AACR cascade for therapeutics-focused work.

Cancer Prevention Research is the AACR cascade for cancer prevention.

Cancer Immunology Research is the AACR cascade for cancer immunology.

Cancer Epidemiology, Biomarkers & Prevention is the AACR cascade for cancer epidemiology and biomarkers.

Cancer Cell is the external Cell Press top-tier cancer cascade. Cancer Cell uses Editorial Manager at Editorial Manager submission portal; editorial contact cancercell@cell.com.

Nature Cancer is the external Springer Nature top-tier cancer cascade.

AACR asks reviewers for an objective overall recommendation supported by detailed comments on the quality and originality of the science and on the applicability and impact of the results and conclusions. The table below maps four review lenses to actionable preparation; the four lenses are Manusights' reading, not an AACR checklist.

In our pre-submission work with Cancer Research-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen.

Narrow cancer-subtype framing flagged at Senior Editor desk screen. When the Cancer Research introduction frames the work too narrowly within one cancer subtype without a broader cancer-research mechanism, Senior Editor desk rejection within the fast AACR triage window is common. The strongest manuscripts make the mechanism visible in the title, abstract, model choice, and first figure, then show why the finding matters beyond the immediate tumor type.

If the abstract only says that a marker is associated with outcome in one cohort, the Senior Editor can often decide before external reviewer recruitment that the paper fits a more specialist AACR or disease-specific venue.

Check whether your Cancer Research mechanism is broad enough →

Clinician-scientist methodology gaps surface as reviewer concerns. When Cancer Research clinical-translation components are present but clinician-scientist methodology is thin, the clinician-scientist reviewer consistently flags the sample-size rationale, randomization, blinding, endpoint definition, and cohort-selection language. The strongest revisions complete CONSORT coverage for any clinical-trial component and align the methods, supplementary tables, and figure legends so the clinical claim does not outrun the evidence package.

Check your Cancer Research clinical-methods package →

AACR family cascade offers from Senior Editor. When the Cancer Research Senior Editor concludes the work is rigorous but the cancer-research mechanism bar is not met, transfer offers to Cancer Discovery, Clinical Cancer Research, Molecular Cancer Therapeutics, or other AACR journals are common. AACR editors take these transfers seriously and the manuscript transfer pathway can preserve reviewer reports.

The decision letter matters: a cascade after a broad-significance concern often means the figure package is sound but the story should be re-aimed, while a cascade after methods concerns usually requires deeper changes before transfer.

Check whether Cancer Research or an AACR sister journal is the better fit →

We have reviewed 50+ manuscripts targeting Cancer Research, Clinical Cancer Research, Cancer Cell, Nature Cancer, and AACR sister journals. This guide tells you what Cancer Research editors look for in the status window, while the review tells you whether your paper passes the same mechanism, figure-order, clinical-methods, and broad-significance checks before the Senior Editor or external reviewers see it. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

We have found that the strongest Cancer Research revisions preserve the same mechanism claim across the title, abstract, first figure, and response letter instead of trying to repair fit only in the cover letter.

In our pre-submission review work across cancer-mechanism and translational oncology targets, Cancer Research-bound drafts most often failed when the central mechanism claim shifted between the abstract, figure sequence, and discussion. We see that inconsistency as a recurring failure pattern because AACR editors can catch the mismatch before external reviewers are invited. Source limitation: official guidance explains AACR editorial workflow and reviewer expectations, but it cannot tell you whether your specific figure order proves the mechanism at Cancer Research depth.

Use this guide when you need to separate normal AACR review silence from a true follow-up moment before you submit, withdraw, or prepare a transfer plan.

This page was created from AACR's public editorial process documentation at the AACR editorial process page, the AACR Manuscript Turnaround Guarantee page (3.8-day median desk decision, 35-day median first decision with peer review, only 3.1 percent of first decisions with peer review exceeding 60 days, 98 percent of first decisions with peer review having 2 or more reviewer comments), the AACR manuscript transfer pathway for inter-AACR-journal cascades, and Manusights pre-submission review experience with Cancer Research-targeted manuscripts.

For the AACR cancer landscape beyond Cancer Research, see Cancer Discovery (top-tier cancer discovery), Clinical Cancer Research (clinical-translation), Molecular Cancer Therapeutics (therapeutics), Cancer Prevention Research (prevention), Cancer Immunology Research (immunology), Cancer Epidemiology, Biomarkers & Prevention (epidemiology), and external cancer alternatives (Cancer Cell, Nature Cancer).

The choice across these titles depends on whether the central contribution is top cancer-research mechanism (Cancer Research), top cancer discovery (Cancer Discovery), clinical-translation (Clinical Cancer Research), therapeutics (Molecular Cancer Therapeutics), prevention (Cancer Prevention Research), immunology (Cancer Immunology Research), epidemiology (Cancer Epidemiology, Biomarkers & Prevention), Cell Press top-tier cancer (Cancer Cell), or Nature Portfolio top-tier cancer (Nature Cancer).

Reviews at Cancer Research are single-blind, and 98 percent of AACR first decisions with peer review in 2024 had comments from 2 or more reviewers. Editors screen and triage manuscripts before any reviewer sees them, and preparing a response template that addresses both basic-cancer-research and clinician-scientist perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Cancer Research cancer-research-mechanism bar before submission, our Cancer Research pre-submission diagnostic flags the framing and methodology weaknesses most likely to surface in reviewer reports.